GLP-ABD-XTEN288

GLP-ABD-XTEN288 is a long-acting **recombinant fusion protein** developed as a glucagon-like peptide-1 (**GLP-1**) receptor agonist. It is engineered by fusing human GLP-1 to both an albumin-binding domain (**ABD**) and an extended **XTEN288** polypeptide sequence, markedly increasing its half-life in circulation compared to native GLP-1. This construct aims to provide prolonged glycemic control and potential anti-obesity effects with less frequent dosing. Like other GLP-1 receptor agonists, it mimics endogenous GLP-1 to stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. The fusion format is designed to overcome the rapid degradation of GLP-1 in vivo and may provide a next-generation option for type 2 diabetes and obesity therapies[1].